{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:39:16Z","timestamp":1792683556806,"version":"4.5.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,13]]},"abstract":"<jats:p>\n                    Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease, and lung cancer is a significant comorbidity with high prevalence and adverse impact on survival. Early detection of IPF and targeted interventions require understanding the associated risk factors and clinical presentation of lung cancer in IPF. This single-center, retrospective cohort study aimed to identify risk factors for lung cancer in IPF patients, investigate its clinical features, and determine its impact on survival. Of the 1481 patients with interstitial lung disease, 436 met the criteria for IPF per American Thoracic Society\/European Respiratory Society guidelines. Patients followed up for\u2005&lt;6 months (n\u2005=\u200531), patients with both IPF and lung cancer (n\u2005=\u200519), and patients whose data were incomplete (n\u2005=\u200518) were excluded from the study. In the end, the study group consisted of 59 patients who developed lung cancer during follow-up, and the control group consisted of 59 randomly selected IPF patients without cancer. Patients\u2019 clinical, radiological, and laboratory data were collected from their medical records. The mean age of the sample, 83.9% of which was male, was 66.9\u2005\u00b1\u20058.3 years. Emphysema, low body mass index, absence of antifibrotic therapy, presence of weight loss symptoms, and\u2005\u226536 pack-years of smoking were significant risk factors for lung cancer (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;.05), as also confirmed by multivariate analysis. Squamous cell carcinoma was the most common histological type (45.8%), with lower lobe predominance (59.3%) and peripheral location (78.0%). Most tumors (78.0%) were within or adjacent to fibrotic tissue. The median time from IPF diagnosis to lung cancer development was 2.80 years. The 0 to 3, 3 to 5, and\u2005&gt;5-year mortality rates for patients with and without lung cancer were 15.2% to 3.3%, 35.5%- 8.4%, and 42.3% to 15.2%, respectively (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.026). Our study identified significant risk factors for lung cancer in IPF patients and demonstrated its negative impact on survival. The presence of emphysema, low body mass index, absence of antifibrotic therapy, and\u2005\u226536 pack-years of smoking were significantly associated with lung cancer development. Awareness of these factors is crucial for early diagnosis and appropriate treatment strategy determination, potentially improving outcomes in this high-risk population.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000047714","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:01:08Z","timestamp":1771005668000},"page":"e47714","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Risk factors, clinical features, and impact on survival of lung cancer in patients with idiopathic pulmonary fibrosis: A retrospective study"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3706-4000","authenticated-orcid":false,"given":"Hasibe \u00c7i\u011fdem","family":"Erten","sequence":"first","affiliation":[{"name":"Department of Pulmonary Diseases, University of Health Sciences, Kartal Dr. L\u00fctfi Kirdar City Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3334-688X","authenticated-orcid":false,"given":"Sevda \u015eener","family":"C\u00f6mert","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases, University of Health Sciences, Kartal Dr. L\u00fctfi Kirdar City Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0875-8409","authenticated-orcid":false,"given":"Talha","family":"Do\u011fruyol","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University of Health Sciences, Kartal Dr. L\u00fctfi Kirdar City Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3449-6916","authenticated-orcid":false,"given":"Ali","family":"Fidan","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases, University of Health Sciences, Kartal Dr. L\u00fctfi Kirdar City Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2280-825X","authenticated-orcid":false,"given":"Gonca G\u00fcl","family":"Ge\u00e7men","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Health Sciences, Kartal Dr. L\u00fctfi Kirdar City Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9670-4472","authenticated-orcid":false,"given":"Cihan Akg\u00fcl","family":"\u00d6zmen","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Health Sciences, Kartal Dr. L\u00fctfi Kirdar City Hospital, Istanbul, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5174-6457","authenticated-orcid":false,"given":"S\u00fcmeyye Kodalak","family":"Cengiz","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases, University of Health Sciences, Kartal Dr. L\u00fctfi Kirdar City Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1987-7619","authenticated-orcid":false,"given":"Saibe Fulya Elmasta\u015f","family":"Akku\u015f","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases, University of Health Sciences, Kartal Dr. L\u00fctfi Kirdar City Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4424-5918","authenticated-orcid":false,"given":"Recep","family":"Demirhan","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University of Health Sciences, Kartal Dr. L\u00fctfi Kirdar City Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260216","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"R2-20260216","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12931-021-01791-z","article-title":"Global incidence and prevalence of idiopathic pulmonary fibrosis.","volume":"22","author":"Maher","year":"2021","journal-title":"Respir Res"},{"key":"R3-20260216","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(11)60052-4","article-title":"Idiopathic pulmonary fibrosis.","volume":"378","author":"King","year":"2011","journal-title":"Lancet"},{"key":"R4-20260216","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3390\/ijms20030593","article-title":"Idiopathic pulmonary fibrosis and lung cancer: mechanisms and molecular targets.","volume":"20","author":"Ballester","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R5-20260216","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1620\/tjem.167.231","article-title":"Lung cancer in patients with idiopathic pulmonary fibrosis.","volume":"167","author":"Nagai","year":"1992","journal-title":"Tohoku J Exp Med"},{"key":"R6-20260216","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/00004728-199611000-00020","article-title":"Lung cancer in patients with idiopathic pulmonary fibrosis: CT findings.","volume":"20","author":"Lee","year":"1996","journal-title":"J Comput Assist Tomogr"},{"key":"R7-20260216","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1183\/09031936.01.99055301","article-title":"Lung cancer in patients with idiopathic pulmonary fibrosis.","volume":"17","author":"Park","year":"2001","journal-title":"Eur Respir J"},{"key":"R8-20260216","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2017.03.016","article-title":"Lung cancer in patients with idiopathic pulmonary fibrosis.","volume":"45","author":"Karampitsakos","year":"2017","journal-title":"Pulm Pharmacol Ther"},{"key":"R9-20260216","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/00063198-200409000-00017","article-title":"Cancer and interstitial lung disease.","volume":"10","author":"Artinian","year":"2004","journal-title":"Curr Opin Pulm Med"},{"key":"R10-20260216","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12931-018-0899-4","article-title":"Characteristics of lung cancer among patients with idiopathic pulmonary fibrosis and interstitial lung disease - analysis of institutional and population data.","volume":"19","author":"Yoon","year":"2018","journal-title":"Respir Res"},{"key":"R11-20260216","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.rmed.2014.07.020","article-title":"Lung cancer in patients with idiopathic pulmonary fibrosis: clinical characteristics and impact on survival.","volume":"108","author":"Lee","year":"2014","journal-title":"Respir Med"},{"key":"R12-20260216","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00408-014-9664-8","article-title":"Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis.","volume":"193","author":"Khan","year":"2015","journal-title":"Lung"},{"key":"R13-20260216","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2478\/raon-2019-0032","article-title":"Idiopathic pulmonary fibrosis in patients with early-stage non-small-cell lung cancer after surgical resection.","volume":"53","author":"Nezka","year":"2019","journal-title":"Radiol Oncol"},{"key":"R14-20260216","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline.","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"R15-20260216","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1378\/chest.14-0359","article-title":"The impact of lung cancer on survival of idiopathic pulmonary fibrosis.","volume":"147","author":"Tomassetti","year":"2015","journal-title":"Chest"},{"key":"R16-20260216","doi-asserted-by":"crossref","first-page":"00111","DOI":"10.1183\/23120541.00111-2016","article-title":"Incidence and predictive factors of lung cancer in patients with idiopathic pulmonary fibrosis.","volume":"4","author":"Kato","year":"2018","journal-title":"ERJ Open Res"},{"key":"R17-20260216","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12890-019-0905-8","article-title":"Risk factors and clinical characteristics of lung cancer in idiopathic pulmonary fibrosis: a retrospective cohort study.","volume":"19","author":"Yoo","year":"2019","journal-title":"BMC Pulm Med"},{"key":"R18-20260216","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1440-1843.2010.01907.x","article-title":"The prevalence of pulmonary fibrosis combined with emphysema in patients with lung cancer.","volume":"16","author":"Usui","year":"2011","journal-title":"Respirology"},{"key":"R19-20260216","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.resinv.2017.09.007","article-title":"Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone.","volume":"56","author":"Miura","year":"2018","journal-title":"Respir Investig"},{"key":"R20-20260216","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/thoraxjnl-2021-218281","article-title":"Impact of antifibrotic therapy on lung cancer development in idiopathic pulmonary fibrosis.","volume":"77","author":"Naoi","year":"2022","journal-title":"Thorax"},{"key":"R21-20260216","doi-asserted-by":"crossref","first-page":"e0202360","DOI":"10.1371\/journal.pone.0202360","article-title":"Lung cancer in idiopathic pulmonary fibrosis: a systematic review and meta-analysis.","volume":"13","author":"JafariNezhad","year":"2018","journal-title":"PLoS One"},{"key":"R22-20260216","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.rmed.2014.01.008","article-title":"How does comorbidity influence survival in idiopathic pulmonary fibrosis?","volume":"108","author":"Hyldgaard","year":"2014","journal-title":"Respir Med"},{"key":"R23-20260216","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1440-1843.2009.01547.x","article-title":"Cumulative incidence of and predictive factors for lung cancer in IPF.","volume":"14","author":"Ozawa","year":"2009","journal-title":"Respirology"},{"key":"R24-20260216","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/01.rct.0000188650.66527.d2","article-title":"High-resolution computed tomography findings of lung cancer associated with idiopathic pulmonary fibrosis.","volume":"30","author":"Kishi","year":"2006","journal-title":"J Comput Assist Tomogr"},{"key":"R25-20260216","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1183\/13993003.01201-2015","article-title":"\u201cScar-cinoma\u201d: viewing the fibrotic lung mesenchymal cell in the context of cancer biology.","volume":"47","author":"Horowitz","year":"2016","journal-title":"Eur Respir J"},{"key":"R26-20260216","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4065\/77.8.763","article-title":"Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis.","volume":"77","author":"Aubry","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"R27-20260216","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12931-016-0398-4","article-title":"A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711\u2009L (PEOPLE Study).","volume":"17","author":"Iwata","year":"2016","journal-title":"Respir Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047714","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T16:02:46Z","timestamp":1771257766000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047714","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"2024-11-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}